



CSE: AIML
OTCQB: AIMLF
FWB: 42FB

NEWS RELEASE

AI/ML INNOVATIONS INC.

AI/ML Innovations Inc.'s Subsidiary Receives Funding Grant for Its Participation in Europe's Largest Study for the Prevention of Loss of Autonomy in the Elderly

Highlights:

- ✓ *The clinical study, led by the University Hospital of Nice, France involves 30,000 patients.*
- ✓ *AI/ML Innovations' subsidiary, Tech2Heal, has been chosen to provide the "technological backbone" for the study.*
- ✓ *Tech2heal has been awarded a funding grant of Euro50,000 in conjunction with this study.*

October 4, 2023 /ACCESSWIRE/

AI/ML Innovations Inc. (the "Company") (CSE - AIML; OTCQB - AIMLF; FWB - 42FB), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to report that its minority-owned subsidiary, Tech2Heal SAS, is the recipient of a funding grant in the amount of Euro50,000 as a result of its participation as the technology partner in Europe's largest study for the "prevention of loss of autonomy in the elderly through the use of personalized care pathways" (the "Study").

As first reported by the Company in a press release dated March 28, 2023, Tech2Heal's Alakin Platform has been chosen as the technological backbone for the University Hospital of Nice, France (CHU) led Study, because of Alakin's ability to create digital care pathways, collect data, engage patients, report their information into a clinical dashboard, integrate local and community services in a geo-localized map, and integrate communication tools. Ultimately, because Alakin is a "no-code configurable platform", it empowers CHU to readily create a completely customized, complex, and intelligent, large-scale clinical trial by configuring Alakin to match CHU's exacting parameters. CHU is conducting the Study in conjunction with ten research laboratories from various fields such as public health, sociology, social and cognitive psychology, physiology, biology, and geography, and will be following a cohort of 30,000 elderly patients for 5 years.

Background of the CHU Study

This highly ambitious project, at the interface of health, innovation and research, aims to make the Nice Côte d'Azur metropolitan area, in conjunction with the University and CHU, a unique territory for experimentation and innovation in the prevention of loss of autonomy. The aim of this participatory science project is to involve 30,000 elderly people over the next 5 years in personalized prevention programs, while enabling companies and researchers to test innovative solutions in this field.

Led by Prof. Zory and Prof. Guerin, the ambition of this project is to shed light, through the production of new and original knowledge, on the issue of accessibility, commitment and effectiveness of programs to prevent loss of autonomy. The project will also focus on the consequences of environmental exposures on loss of autonomy, the empowerment of the elderly in their care, the use of digital solutions to optimize the match between resources and needs, and the individualization of prevention by taking into account social, cultural, economic and environmental factors. The project will put participants at the heart of prevention by offering them personalized prevention paths, and by creating a community of users who will participate in the development and evaluation of the project.

An individualized 12-week program will be offered, with digital, videoconference or face-to-face interventions. Participants will be reassessed after the course and monitored for a year. A digital platform will be used to communicate with participants and collect data. The project is ambitious in terms of its interdisciplinary structure and immediate societal impact. The aim is to include 5,000 patients over 60 who are geographically, socially or digitally isolated from the healthcare system, and more specifically from prevention programs. The project involves ten research laboratories covering various fields such as public health, sociology, social and cognitive psychology, physiology, biology and geography.



Tech2heal

About Tech2heal <https://www.tech2heal.com/>

Tech2heal's Alakin Digital Health Platform is at the forefront of transforming healthcare delivery, empowering healthcare professionals, researchers, and institutions with advanced tools and automation. The platform's AI-powered capabilities facilitate a shift towards patient-centered care, improving outcomes and alleviating the global scarcity of healthcare professionals.



About AI/ML Innovations Inc. <https://aiml-innovations.com/>

AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge (95.2% owned by AIML), Tech2Heal (up to 22% ownership rights, with 12.44% currently owned by AIML), AI Rx Inc. (70% owned by AIML) and other planned accretive investments, the Company continues to capitalize on expanding growth areas, to the benefit of all the Company's stakeholders. AI/ML's shares are traded on the Canadian Securities Exchange under the symbol "AIML", the OTCQB Venture Market under "AIMLF", and the Frankfurt Stock Exchange under "42FB".

On behalf of the Board of Directors
Tim Daniels, Executive Chairman

For more information about AI/ML Innovations:

For detailed information please see AI/ML's website or the Company's filed documents at www.sedar.com.
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com.

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

For AI/ML Innovations Investors

Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at www.sedar.com.